Upcoming therapeutic targets in cutaneous lupus erythematous

References

• Wenzel J, Zahn S, Tuting T. Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus. 2010;19(9):1020–1028.
   PubMed Web of Science ®Google Scholar
• Wenzel J, Zahn S, Bieber T, et al. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301(1):83–86.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. 2014;47(2):148–162.
   PubMed Web of Science ®Google Scholar
• Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36(8):481–490.
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–2615.
   PubMed Web of Science ®Google Scholar
• Dey-Rao R, Sinha AA. Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation. Genomics. 2015;105(2):90–100.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Suarez-Farinas M, Fuentes-Duculan J, et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol. 2014;134(1):87–95.
   PubMed Web of Science ®Google Scholar
• Braegelmann C, Hoelzel M, Ludbrook V, et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp Dermatol. Forthcoming 2016.
   PubMedGoogle Scholar
• Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 2009;4(1):44–57.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011;65(6):e179–193.
   PubMedGoogle Scholar
• Sigges J, Biazar C, Landmann A, et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013;12(7):694–702.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011;65(6):e195–e213.
   PubMedGoogle Scholar
• Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10(10):727–732.
   PubMed Web of Science ®Google Scholar
• Hofmann SC, Leandro MJ, Morris SD, et al. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus–report of 17 cases and review of the literature. Lupus. 2013;22(9):932–939.
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–2379.
   PubMed Web of Science ®Google Scholar
• Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol. 2015;6:550.
   PubMed Web of Science ®Google Scholar
• Paran D, Naparstek Y. Is B cell-targeted therapy effective in systemic lupus erythematosus? Isr Med Assoc J. 2015;17(2):98–103.
   PubMed Web of Science ®Google Scholar
• Dorner T, Shock A, Goldenberg DM, et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: implications for the treatment of systemic lupus erythematosus. Autoimmun Rev. 2015;14(12):1079–1086.
   PubMed Web of Science ®Google Scholar
• Rao V, Gordon C. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. Immunotherapy. 2014;6(11):1165–1175.
   PubMed Web of Science ®Google Scholar
• Huard B, Tran NL, Benkhoucha M, et al. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One. 2012;7(2):e31837.
   PubMed Web of Science ®Google Scholar
• Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005;52(7):2080–2091.
   PubMed Web of Science ®Google Scholar
• Weintraub B. Belimumab efficacy is ‘mild’ but market potential still great: anticipating US approval of the first lupus drug since 1957. BioDrugs. 2011;25(3):203–205.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–2015.
   PubMed Web of Science ®Google Scholar
• Wenzel J, Bauer R, Bieber T, et al. Autoantibodies in patients with lupus erythematosus: spectrum and frequencies. Dermatology. 2000;201(3):282–283.
   PubMed Web of Science ®Google Scholar
• Chong BF, Tseng LC, Kim A, et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci. 2014;73(3):216–224.
   PubMed Web of Science ®Google Scholar
• Scheinberg M, Golmia R. Real life experience on the effect of belimumab in patients with active systemic lupus. SpringerPlus. 2014;3:758.
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. Taming lupus – a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871–882.
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011–1021.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202.
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Ducreux J, Houssiau FA. Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford). 2014;53(8):1369–1376.
   PubMed Web of Science ®Google Scholar
• Wang B, Higgs BW, Chang L, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin Pharmacol Ther. 2013;93(6):483–492.
   PubMed Web of Science ®Google Scholar
• Furie RMJ, Werth V, Khamashta M, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheumatol. 2015;67(suppl 10):A 3223.
   Google Scholar
• Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2014;23(1):7–11.
   PubMed Web of Science ®Google Scholar
• Clark DN, Markham JL, Sloan CS, et al. Cytokine inhibition as a strategy for treating systemic lupus erythematosus. Clin Immunol. 2013;148(3):335–343.
   PubMed Web of Science ®Google Scholar
• Zahn S, Rehkamper C, Kummerer BM, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131(1):133–140.
   PubMed Web of Science ®Google Scholar
• Rommler F, Hammel M, Waldhuber A, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015;10(2):e0116703.
   Web of Science ®Google Scholar
• Lenert P. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol. 2010;161(2):208–222.
   PubMed Web of Science ®Google Scholar
• Wenzel J, Van Holt N, Maier J, et al. JAK-1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. Forthcoming 2016.
   PubMedGoogle Scholar
• Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7):681–683.
   PubMed Web of Science ®Google Scholar
• Bhat S, Sujatha D. A clinical evaluation of 5% amlexanox oral paste in the treatment of minor recurrent aphthous ulcers and comparison with the placebo paste: a randomized, vehicle controlled, parallel, single center clinical trial. Indian J Dent Res. 2013;24(5):593–598.
   PubMedGoogle Scholar
• Workman P, Clarke PA, Raynaud FI, et al. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010;70(6):2146–2157.
   PubMed Web of Science ®Google Scholar
• Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369(2):197–198.
   PubMed Web of Science ®Google Scholar
• Pomel V, Klicic J, Covini D, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem. 2006;49(13):3857–3871.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–355.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340.
   PubMed Web of Science ®Google Scholar
• Projan SJ, Gill D, Lu Z, et al. Small molecules for small minds? The case for biologic pharmaceuticals. Expert Opin Biol Ther. 2004;4(8):1345–1350.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol. 2007;143(2):233–236.
   PubMedGoogle Scholar
• Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–1844.
   PubMed Web of Science ®Google Scholar
• Ports WC, Feldman SR, Gupta P, et al. Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design. J Drugs Dermatol. 2015;14(8):777–784.
   PubMed Web of Science ®Google Scholar
• Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest. 2005;115(4):996–1005.
   PubMed Web of Science ®Google Scholar
• Gomez-Martin D, Diaz-Zamudio M, Crispin JC, et al. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun Rev. 2009;9(1):34–39.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76(2):280–287.
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang Y, Qin B, et al. A meta-analysis of the association of IL-6 −174 G/C and −572 G/C polymorphisms with systemic lupus erythematosus risk. Rheumatol Int. 2014;34(2):199–205.
   PubMed Web of Science ®Google Scholar
• Lee YH, Choi SJ, Ji JD, et al. Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis. Inflamm Res. 2012;61(9):949–954.
   PubMed Web of Science ®Google Scholar
• Thomas S, Fisher K, Snowden J, et al. Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. Lancet. 2015;385(Suppl 1):S98.
   PubMedGoogle Scholar
• Saleiro D, Platanias LC. Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 2015;36(1):21–29.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–4804.
   PubMed Web of Science ®Google Scholar
• Allam R, Pawar RD, Kulkarni OP, et al. Viral 5ʹ-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol. 2008;38(12):3487–3498.
   PubMed Web of Science ®Google Scholar
• Unterholzner L. The interferon response to intracellular DNA: why so many receptors? Immunobiology. 2013;218(11):1312–1321.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):145–153.
   PubMed Web of Science ®Google Scholar
• Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537–2538.
   PubMed Web of Science ®Google Scholar
• Abe T, Barber GN. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J Virol. 2014;88(10):5328–5341.
   PubMed Web of Science ®Google Scholar
• Llona-Minguez S, Baiget J, Mackay SP. Small-molecule inhibitors of IkappaB kinase (IKK) and IKK-related kinases. Pharm Pat Anal. 2013;2(4):481–498.
   PubMedGoogle Scholar
• Smith S, Gabhann JN, Higgs R, et al. Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus. Arthritis Rheum. 2012;64(5):1601–1609.
   PubMed Web of Science ®Google Scholar
• Qureshi N, Morrison DC, Reis J. Proteasome protease mediated regulation of cytokine induction and inflammation. Biochim Biophys Acta. 2012;1823(11):2087–2093.
   PubMed Web of Science ®Google Scholar
• Ackermann JA, Nys J, Schweighoffer E, et al. Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival. J Immunol. 2015;194(10):4650–4656.
   PubMed Web of Science ®Google Scholar
• Clark K, Plater L, Peggie M, et al. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem. 2009;284(21):14136–14146.
   PubMed Web of Science ®Google Scholar
• Holcomb R, Suzuki K, Halter RJ et al. Amino – pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon. (Ed.^(Eds) (Google Patents, 2011).
   Google Scholar
• Shu C, Sankaran B, Chaton CT, et al. Structural insights into the functions of TBK1 in innate antimicrobial immunity. Structure. 2013;21(7):1137–1148.
   PubMed Web of Science ®Google Scholar
• Fu J, Zhu X, Dan H, et al. Amlexanox is as effective as dexamethasone in topical treatment of erosive oral lichen planus: a short-term pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(5):638–643.
   PubMed Web of Science ®Google Scholar
• Hasan M, Dobbs N, Khan S, et al. Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. J Immunol. 2015;195(10):4573–4577.
   PubMed Web of Science ®Google Scholar
• Jeong Y, Kwon D, Hong S. Selective and potent small-molecule inhibitors of PI3Ks. Future Med Chem. 2014;6(7):737–756.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev. 2009;228(1):253–272.
   PubMed Web of Science ®Google Scholar
• Suarez-Fueyo A, Rojas JM, Cariaga AE, et al. Inhibition of PI3Kdelta reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol. 2014;193(2):544–554.
   PubMed Web of Science ®Google Scholar
• Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med. 2005;11(9):933–935.
   PubMed Web of Science ®Google Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364–1374.
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756–758.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202.
   PubMed Web of Science ®Google Scholar
• Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C, et al. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus. 2007;16(10):775–781.
   PubMed Web of Science ®Google Scholar
• Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2983–2988.
   PubMed Web of Science ®Google Scholar
• Carr TD, DiGiovanni J, Lynch CJ, et al. Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival. Cancer Prev Res (Phila). 2012;5(12):1394–1404.
   PubMed Web of Science ®Google Scholar
• Lai ZW, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64(9):2937–2946.
   PubMed Web of Science ®Google Scholar
• Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2(9):717–726.
   PubMed Web of Science ®Google Scholar
• Waetzig GH, Seegert D, Rosenstiel P, et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol. 2002;168(10):5342–5351.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Wada T, Furuichi K, et al. p38 mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol. 2003;14(1):57–67.
   PubMed Web of Science ®Google Scholar
• Sun W, Jiao Y, Cui B, et al. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest. 2013;93(6):626–638.
   PubMed Web of Science ®Google Scholar
• Zhi-Chun L, Qiao-Ling Z, Zhi-Qin L, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis. Inflammation. 2012;35(3):935–943.
   PubMed Web of Science ®Google Scholar
• Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387–402.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Molloy E, Berger J. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol. 2015;11(2):119–123.
   PubMed Web of Science ®Google Scholar
• Tan S-L, Liao C, Lucas MC, et al. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol Ther. 2013;138(2):294–309.
   PubMed Web of Science ®Google Scholar
• Grammatikos AP, Ghosh D, Devlin A, et al. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS One. 2013;8(8):e74550.
   PubMed Web of Science ®Google Scholar
• Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs. 2009;12(3):174–185.
   PubMed Web of Science ®Google Scholar
• Iwata S, Yamaoka K, Niiro H, et al. [Involvement of Syk in pathology of systemic autoimmune disease]. Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(1):56–61.
   PubMedGoogle Scholar
• Deng GM, Liu L, Bahjat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010;62(7):2086–2092.
   PubMed Web of Science ®Google Scholar
• Koga T, Ichinose K, Mizui M, et al. Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. J Immunol. 2012;189(7):3490–3496.
   PubMed Web of Science ®Google Scholar
• Ichinose K, Juang YT, Crispin JC, et al. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 2011;63(2):523–529.
   PubMed Web of Science ®Google Scholar
• Koga T, Mizui M, Yoshida N, et al. KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3(+) regulatory T cells in MRL/lpr mice. Autoimmunity. 2014;47(7):445–450.
   PubMed Web of Science ®Google Scholar
• Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127(2):303–312; quiz 313–304.
   PubMed Web of Science ®Google Scholar
• Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64(4):630–633.
   PubMed Web of Science ®Google Scholar
• Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994;94(2):585–591.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–552.
   PubMed Web of Science ®Google Scholar
• Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118–128.
   PubMed Web of Science ®Google Scholar
• Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18(2):92–95.
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038.
   PubMed Web of Science ®Google Scholar
• Cunninghame Graham DS, Morris DL, Bhangale TR, et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 2011;7(10):e1002341.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yokoyama Y, Shimizu Y, et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod Rheumatol. 2015;1–2. doi:10.3109/14397595.2015.1069473. [Epub ahead of print]
   Google Scholar
• Fukuyama T, Ehling S, Cook E, et al. Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394–405.
   PubMed Web of Science ®Google Scholar
• Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–399.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151:1110.
   PubMed Web of Science ®Google Scholar
• Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73(12):2192–2198.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64(3):617–629.
   PubMed Web of Science ®Google Scholar
• Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011;2011:208–214.
   PubMed Web of Science ®Google Scholar
• Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171(1):60–73.
   PubMed Web of Science ®Google Scholar
• Pattison MJ, Mackenzie KF, Arthur JS. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol. 2012;189(6):2784–2792.
   PubMed Web of Science ®Google Scholar
• Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–3842.
   PubMed Web of Science ®Google Scholar
• Chan ES, Herlitz LC, Ali J. Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model. J Invest Dermatol. 2015;135(9):2338–2339.
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049.
   PubMed Web of Science ®Google Scholar
• Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–664.
   PubMed Web of Science ®Google Scholar